{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:01:32Z","timestamp":1792195292314,"version":"4.4.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007492","name":"Baylor University","doi-asserted-by":"publisher","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/100007492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200614"],"award-info":[{"award-number":["RP200614"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA244579"],"award-info":[{"award-number":["R01CA244579"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA142543"],"award-info":[{"award-number":["P30 CA142543"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1S10 RR024757"],"award-info":[{"award-number":["1S10 RR024757"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA238624"],"award-info":[{"award-number":["R01CA238624"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CPRIT RP210099"],"award-info":[{"award-number":["CPRIT RP210099"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["SCR_017949"],"award-info":[{"award-number":["SCR_017949"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023736","name":"Office of the Vice President for Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejmech.2023.115794","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T10:06:10Z","timestamp":1693994770000},"page":"115794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Synthesis and biological evaluation of structurally diverse 6-aryl-3-aroyl-indole analogues as inhibitors of tubulin polymerization"],"prefix":"10.1016","volume":"263","author":[{"given":"Wen","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob D.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Vairin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoli","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashini I.","family":"Wanniarachchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khagendra B.","family":"Hamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouguiniseli E.","family":"Tankoano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb S.","family":"Tamminga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena M.A.","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph P.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lynn","family":"Trawick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1262-8631","authenticated-orcid":false,"given":"Kevin G.","family":"Pinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115794_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.132723","article-title":"Microtubules destabilizing agents binding sites in tubulin","volume":"1259","author":"Alpizar-Pedraza","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2023.115794_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1039\/C3NP70092E","article-title":"Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities","volume":"31","author":"Rohena","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejmech.2023.115794_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0163-7258(91)90067-V","article-title":"Interactions of colchicine with tubulin","volume":"51","author":"Hastie","year":"1991","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115794_bib4","first-page":"203","article-title":"Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs","volume":"15","author":"Pettit","year":"2000","journal-title":"Anti Cancer Drug Des."},{"key":"10.1016\/j.ejmech.2023.115794_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01954881","article-title":"Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor","volume":"45","author":"Pettit","year":"1989","journal-title":"Experientia"},{"key":"10.1016\/j.ejmech.2023.115794_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0378-5173(01)00986-3","article-title":"Paclitaxel and its formulations","volume":"235","author":"Singla","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2023.115794_bib7","first-page":"2325","article-title":"Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action","volume":"55","author":"Bollag","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115794_bib8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1124\/mol.52.4.613","article-title":"The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells","volume":"52","author":"Kowalski","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115794_bib9","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"Dumontet","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115794_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115687","article-title":"Design, synthesis, and biological evaluation of 3, 5-disubsituted-1H-pyrazolo [3, 4-b] pyridines as multiacting inhibitors against microtubule and kinases","author":"Ning","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115470","article-title":"Discovery of novel N-aryl-2-trifluoromethyl-quinazoline-4-amine derivatives as the inhibitors of tubulin polymerization in leukemia cells","volume":"256","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115437","article-title":"Discovery of novel 6-p-tolyl-3-(3, 4, 5-trimethoxybenzyl)-7H-[1, 2, 4] triazolo [3, 4-b][1, 3, 4] thiadiazine derivative as a potent tubulin inhibitor with promising in vivo antitumor activity","volume":"256","author":"Ji","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115402","article-title":"Discovery of 6-aryl-2-(3, 4, 5-trimethoxyphenyl) thiazole [3, 2-b][1, 2, 4] triazoles as potent tubulin polymerization inhibitors","volume":"256","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115284","article-title":"Design, synthesis, and biological evaluation of diaryl heterocyclic derivatives targeting tubulin polymerization with potent anticancer activities","volume":"252","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib15","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s11095-012-0828-z","article-title":"An overview of tubulin inhibitors that interact with the colchicine binding site","volume":"29","author":"Lu","year":"2012","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejmech.2023.115794_bib16","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.4155\/fmc-2017-0100","article-title":"Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures","volume":"9","author":"Li","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib17","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.2174\/0929867326666191003154051","article-title":"Tubulin inhibitors binding to colchicine-site: a review from 2015 to 2019","volume":"27","author":"Xia","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib18","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1158\/1535-7163.MCT-09-0815","article-title":"BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy","volume":"9","author":"Kremmidiotis","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115794_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF00210783","article-title":"Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor","volume":"14","author":"Dorr","year":"1996","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2023.115794_bib20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1517\/13543776.12.6.769","article-title":"Small-molecule, tubulin-binding compounds as vascular targeting agents","volume":"12","author":"Marx","year":"2002","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.115794_bib21","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1182\/blood-2010-12-323857","article-title":"A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells","volume":"117","author":"Singh","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115794_bib22","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1039\/C8MD00322J","article-title":"Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents","volume":"9","author":"Maguire","year":"2018","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2023.115794_bib23","series-title":"U.S. Patent, Filed on March 12, 2001. Issued (US Patent 6,593,374) July 15","article-title":"Tubulin binding ligands and corresponding prodrug constructs","author":"Pinney","year":"2003"},{"key":"10.1016\/j.ejmech.2023.115794_bib24","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bmc.2016.01.007","article-title":"Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents","volume":"24","author":"Devkota","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib25","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.1016\/j.bmc.2015.10.012","article-title":"Structural interrogation of benzosuberene-based inhibitors of tubulin polymerization","volume":"23","author":"Herdman","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib26","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1021\/acs.jmedchem.9b00551","article-title":"Structure guided design, synthesis, and biological evaluation of novel benzosuberene analogues as inhibitors of tubulin polymerization","volume":"62","author":"Niu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tetlet.2018.12.033","article-title":"Efficient synthetic methodology for the construction of dihydronaphthalene and benzosuberene molecular frameworks","volume":"60","author":"Mondal","year":"2019","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2023.115794_bib28","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1016\/j.bmc.2008.07.050","article-title":"Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy","volume":"16","author":"Sriram","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib29","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1039\/c2md00318j","article-title":"An amino-benzosuberene analogue that inhibits tubulin assembly and demonstrates remarkable cytotoxicity","volume":"3","author":"Tanpure","year":"2012","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2023.115794_bib30","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1039\/C6MD00459H","article-title":"Synthesis and biological evaluation of benzocyclooctene-based and indene-based anticancer agents that function as inhibitors of tubulin polymerization","volume":"7","author":"Herdman","year":"2016","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2023.115794_bib31","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0960-894X(99)00143-2","article-title":"A new anti-tubulin agent containing the benzo[b]thiophene ring system","volume":"9","author":"Pinney","year":"1999","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115794_bib32","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1016\/j.bmc.2013.07.028","article-title":"Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3'-hydroxy-4'-methoxyphenyl)-3-(3'',4'',5''-trimethoxybenzoyl)-6-methoxyindole (OXi8006)","volume":"21","author":"MacDonough","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib33","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1021\/np400374w","article-title":"Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agent","volume":"76","author":"Hadimani","year":"2013","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2023.115794_bib34","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200145","article-title":"Oral sabizabulin for high-risk, hospitalized adults with Covid-19: interim analysis","volume":"1","author":"Barnette","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.ejmech.2023.115794_bib35","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1021\/jm4001117","article-title":"Discovery of 4-aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties","volume":"56","author":"Xiao","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib36","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1021\/jm300564b","article-title":"Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents","volume":"55","author":"Chen","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib37","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1007\/s11095-012-0814-5","article-title":"Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer","volume":"29","author":"Li","year":"2012","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejmech.2023.115794_bib38","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1021\/acs.jmedchem.9b00706","article-title":"Structure-guided design, synthesis, and biological evaluation of (2-(1H-Indol-3-yl)-1H-imidazole-4-yl)(3, 4, 5-trimethoxyphenyl) methanone (ABI-231) analogues targeting the colchicine binding site in tubulin","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib39","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-22-0162","article-title":"A phase Ib\/II study of sabizabulin, a novel oral cytoskeleton disruptor, in men with metastatic castration-resistant prostate cancer with progression on an androgen receptor-targeting agent","volume":"28","author":"Markowski","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115794_bib40","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1039\/c0ib00135j","article-title":"A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment","volume":"3","author":"Mason","year":"2011","journal-title":"Integr. Biol."},{"key":"10.1016\/j.ejmech.2023.115794_bib41","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1158\/1078-0432.416.11.2","article-title":"Differentiation and definition of vascular-targeted therapies","volume":"11","author":"Siemann","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115794_bib42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1586\/14737140.4.2.321","article-title":"Targeting the tumor vasculature: a strategy to improve radiation therapy","volume":"4","author":"Siemann","year":"2004","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2023.115794_bib43","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1628","article-title":"Disrupting tumour blood vessels","volume":"5","author":"Tozer","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115794_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173692","article-title":"Vascular disrupting agents in cancer therapy","volume":"891","author":"Smolarczyk","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115794_bib45","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.3390\/molecules26092551","article-title":"Non-invasive evaluation of acute effects of tubulin binding agents: a review of imaging vascular disruption in tumors","volume":"26","author":"Liu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115794_bib46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.canlet.2015.08.021","article-title":"The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts","volume":"369","author":"Strecker","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2023.115794_bib47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/978-1-59745-184-0_17","article-title":"Small-molecule vascular disrupting agents in cancer therapy","author":"Siemann","year":"2008","journal-title":"Antiangiogenic Agents in Cancer Therapy"},{"key":"10.1016\/j.ejmech.2023.115794_bib48","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.ijrobp.2004.08.002","article-title":"Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors","volume":"60","author":"Siemann","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejmech.2023.115794_bib49","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1158\/0008-5472.CAN-20-0373","article-title":"Preclinical applications of multi-platform imaging in animal models of cancer","volume":"81","author":"Serkova","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115794_bib50","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.3390\/cancers13194769","article-title":"Imaging-guided evaluation of the novel small-molecule benzosuberene tubulin-binding agent KGP265 as a potential therapeutic agent for cancer treatment","volume":"13","author":"Guo","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115794_bib51","article-title":"Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115794_bib52","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1096\/fj.07-103713","article-title":"Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging (BLI) and confirmed by magnetic resonance imaging (MRI)","volume":"22","author":"Zhao","year":"2008","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2023.115794_bib53","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/acs.jnatprod.9b00773","article-title":"Bioreductively activatable prodrug conjugates of combretastatin A-1 and combretastatin A-4 as anticancer agents targeted toward tumor-associated hypoxia","volume":"83","author":"Winn","year":"2020","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2023.115794_bib54","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s11307-016-0963-8","article-title":"Bioluminescence and MR imaging of the safety and efficacy of vascular disruption in gliomas","volume":"18","author":"Folaron","year":"2016","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.ejmech.2023.115794_bib55","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/molecules21101375","article-title":"Novel natural product- and privileged scaffold-based tubulin inhibitors targeting the colchicine binding site","volume":"21","author":"Dong","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115794_bib56","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1021\/acs.jmedchem.9b01815","article-title":"Structure\u2013activity relationship study of novel 6-aryl-2-benzoyl-pyridines as tubulin polymerization inhibitors with potent antiproliferative properties","volume":"63","author":"Chen","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejmech.2018.04.042","article-title":"New 6-and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors","volume":"152","author":"La Regina","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib58","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ejmech.2018.09.045","article-title":"Conformation impacts on the bioactivities of SMART analogues","volume":"158","author":"Wu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib59","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1158\/0008-5472.CAN-17-0577","article-title":"A Potent, metabolically stable tubulin inhibitor targets the colchicine binding site and overcomes taxane resistance","volume":"78","author":"Arnst","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115794_bib60","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/med.21568","article-title":"Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy","volume":"39","author":"Arnst","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2023.115794_bib61","doi-asserted-by":"crossref","first-page":"12049","DOI":"10.1021\/acs.jmedchem.1c00715","article-title":"Design, synthesis, and biological evaluation of stable colchicine-binding site tubulin inhibitors 6-aryl-2-benzoyl-pyridines as potential anticancer agents","volume":"64","author":"Chen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib62","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.3390\/cancers14215336","article-title":"Sabizabulin, a potent orally bioavailable colchicine binding site agent, suppresses HER2+ breast cancer and metastasis","volume":"14","author":"Krutilina","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115794_bib63","first-page":"143","article-title":"Evaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI","volume":"5","author":"Zhou","year":"2015","journal-title":"J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ejmech.2023.115794_bib64","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1016\/j.tetlet.2015.01.129","article-title":"Mechanistic considerations in the synthesis of 2-aryl-indole analogues under Bischler-Mohlau conditions","volume":"56","author":"MacDonough","year":"2015","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2023.115794_bib65","article-title":"Indole compounds","volume":"vol. 933","author":"Hsieh","year":"2005"},{"key":"10.1016\/j.ejmech.2023.115794_bib66","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1021\/cr00039a007","article-title":"Palladium-catalyzed cross-coupling reactions of organoboron compounds","volume":"95","author":"Miyaura","year":"1995","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2023.115794_bib67","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1021\/jm000045a","article-title":"Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug","volume":"43","author":"Pettit","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115794_bib68","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature02393","article-title":"Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain","volume":"428","author":"Ravelli","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115794_bib69","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1016\/j.bmcl.2013.10.039","article-title":"New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation","volume":"23","author":"Chen","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115794_bib70","doi-asserted-by":"crossref","first-page":"31654","DOI":"10.1039\/C9RA05532K","article-title":"Enantioselective bromination of axially chiral cyanoarenes in the presence of bifunctional organocatalysts","volume":"9","author":"Wada","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2023.115794_bib71","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1021\/np070377j","article-title":"Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents","volume":"71","author":"Siles","year":"2008","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2023.115794_bib72","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nprot.2006.179","article-title":"Sulforhodamine B colorimetric assay for cytotoxicity screening","volume":"1","author":"Vichai","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2023.115794_bib73","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","article-title":"Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines","volume":"83","author":"Monks","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2023.115794_bib74","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4161\/cam.36224","article-title":"An introduction to the wound healing assay using live-cell microscopy","volume":"8","author":"Jonkman","year":"2014","journal-title":"Cell Adhes. Migrat."},{"key":"10.1016\/j.ejmech.2023.115794_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202300230","article-title":"Breaking a dogma: high\u2010throughput live\u2010cell imaging in real\u2010time with Hoechst 33342","author":"Fuchs","year":"2023","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.ejmech.2023.115794_bib76","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/nprot.2006.238","article-title":"Analysis of apoptosis by propidium iodide staining and flow cytometry","volume":"1","author":"Riccardi","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2023.115794_bib77","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0304-4165(81)90231-2","article-title":"Stabilization of the colchicine-binding activity of tubulin by organic acids","volume":"675","author":"Hamel","year":"1981","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2023.115794_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/CBB:38:1:1","article-title":"Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin","volume":"38","author":"Hamel","year":"2003","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2023.115794_bib79","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/nprot.2014.108","article-title":"Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing","volume":"9","author":"Pavia-Jimenez","year":"2014","journal-title":"Nat. Protoc."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:05:06Z","timestamp":1777529106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423007614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":79,"alternative-id":["S0223523423007614"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115794","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and biological evaluation of structurally diverse 6-aryl-3-aroyl-indole analogues as inhibitors of tubulin polymerization","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115794","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115794"}}